Pfizer Reports Five-Year CROWN Trial Data for Lorbrena in ALK-Positive NSCLC

Pfizer today presented five-year progression-free survival data from the Phase 3 CROWN trial evaluating Lorbrena (lorlatinib) versus crizotinib as first-line treatment for ALK-positive non-small cell lung cancer. The data showed that 60% of patients in the Lorbrena arm remained progression-free at five years compared to 8% in the crizotinib arm.